Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells

Immunology

Volumn 97, Issue 4, 1999, Pages 616-625

  Cao, Xuetao ^a   Zhang, W ^a   Wang, J ^a   Zhang, M ^a   Huang, X ^a   Hamada, H ^b   Chen, W ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Foundation for the Promotion of Cancer Research (Japan)   (Japan)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNOMODULATION; IMMUNOSTIMULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CANCER VACCINES; CELL FUSION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOPHENOTYPING; LUNG NEOPLASMS; LYMPHOCYTE CULTURE TEST, MIXED; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPLEEN; T-LYMPHOCYTE SUBSETS;

EID: 0032781867     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1999.00823.x     Document Type: Article

References (50)

1. 1. FINN O.J. (1993) Tumor-rejection antigens recognized by T lymphocytes. Curr Opin Immunol 5, 701.
2. 2. BOON T., CEROTTINI J.C., VAN DEN EYNDE B., VAN DER BRUGGEN P. & VAN PEL A. (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12, 37.
3. 3. ROSENBERG S. A. (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18, 175.
4. 4. CHEN L., ASHE S., BRADY W.A. et al. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093.
5. 5. RESTIFO N.P., ESQUIVEL F., KAWAKAMI Y. et al. (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177, 265.
6. 6. CHEN H.L., GABRILOVICH D., TAMPE R., GIRGIS K.R., NADAF S. & CARBONE D.P. (1996) A functionally defective allele of TAP 1 results in loss of MHC class I antigen presentation in a human lung cancer. Nature Genet 13, 210.
7. 7. BASKAR S., OSTRAND-ROSENBERG S., NABAVI N., NADLER L.M., FREEMAN G.J. & GLIMCHER L.H. (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90, 5687.
8. 8. DRANOFF G., JAFFEE E., LAZENBY A. et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90, 35.
9. 9. TOWNSEND S.E. & ALLISON J.P. (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 368.
10. 10. YOUNG J.W. & INABA K. (1996) Dendritic cells as aduvants for class I major histocompatibility complex-restricted antitumur immunity. J Exp Med 183, 7.
11. 11. SCHULER G. & STEINMAN R.M. (1997) Dendritic cells as adjuvants for immune-mediated resistance to tumor. J Exp Med 186, 1183.
12. 12. CAO X.T., ZHANG W.P., MA S.H., ZHANG M.H., WANG J.L. & YE T. (1997) Enhanced antitumor effects of tumor antigen-pulsed dendritic cells by their transfection with GM-CSF gene. Sci China (Ser C) 40, 539.
13. 13. AHUJA S., MUMMIDI S., MALECH H. & AHUJA S.K. (1998) Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-gamma and IL-12. J Immnunol 161, 868.
14. 14. CAO X., ZHANG W., HE L. et al. (1998) Lymphotactin genemodified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 161, 6238.
15. 15. MAYORDOMO J.I., ZORINA T., STORKUS W.J. et al. (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1, 1297.
16. 16. PORGADOR A. & GILLBOA E. (1995) Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182, 255.
17. 17. BOCZKOWSKI D., NAIR S., SNYDER D. & GILBOA E. (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184, 465.
18. 18. CELLUZZI C.M., MAYORDOMO J.I., STORKUS W.J., LOTZE M.T. & FALO L.D., JR (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183, 283.
19. 19. PAGLIA P., CHIODONI C., RODOLFO M. & COLOMBO M.P. (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183, 317.
20. 20. REEVES M., ROYAL R.E., LAM J.S., ROSENBERG, S.A. & HWU P. (1996) Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 56, 5672.
21. 21. SONG W., KONG H., CARPENTER H. et al. (1997) Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective and therapeutic antitumor immunity. J Exp Med 186, 1247.
22. 22. GUO Y., WU M., CHEN H. et al. (1994) Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263, 518.
23. 23. GONG J., CHEN D., KASHIWABA M. & KUFE D. (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med 3, 558.
24. 24. WANG J., SAFFOLD S., CAO X., KRAUSS J. & CHEN W. (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161, 5516.
25. 25. STEINMAN R.M. (1991) The dendritic cells system and its role in immunogenicity. Annu Rev Immunol 9, 271.
26. 26. HART D.N.J. (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90, 3245.
27. 27. BANCHEREAU J. & STEINMAN R. (1998) Dendritic cells and the control of immunity. Nature 392, 245.
28. 28. WILTMER-PACK M.D., OLIVIER W., VALINSKY J., SCHULER G. & STEINMAN R.M. (1987) Granulocyte macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans' cells. J Exp Med 166, 1484.
29. 29. MARKOWICZ S. & ENGLEMAN E.G. (1990) Granulocyte macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 85, 955.
30. 30. TAZI A., BOUCHONNET F., GRANDSAIGNE M., BOUMSELL L., HANCE A.J. & SOLER P. (1993) Evidence that granulocyte macrophage colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans' cells in human lung and lung cancers. J Clin Invest 91, 566.
31. 31. LARSEN C., RITCHIE S.C. & HENDRIX R. et al. (1994) Regulation of immunostimulatory function and costimulatory molecule (B7 and B7) expression on murine dendritic cells. J Immunol 152, 5208.
32. 32. SALLUSTO F, & LANZAVECCHIA A. (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J Exp Med 179, 1109.
33. 33. HAYASHI H., MATSUBARA H., YOKOTA T. et al. (1992) Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection. J Immunol 149, 1223.
34. 34. ABE J., WAKIMOTO H., YOSHIDA Y., AOYAGI M., HIRAKAWA K. & HAMADA H. (1995) Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus-and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 121, 587.
35. 35. METLAY J.P., WITMER-PACK M.D., AGGER R., CROWLEY M.T., LAWLESS D. & STEINMAN R.M. (1990) The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med 171, 1753.
36. 36. TUTING T., DELEO A.B., LOTZE M.T. & STORKUS W.J. (1997) Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo. Eur J Immunol 27, 2702.
37. 37. ZITVOGEL L., MAYORDOMO J.I., TJANDRAWAN T. et al. (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell l-associated cytokines. J Exp Med 183, 87.
38. 38. ZHANG W., HE L., YUAN Z. et al. (1999) Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Human Gene Ther 10, 1151.
39. 39. MARASKOVSKY E., BRASEL K., TEEPE M. et al. (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184, 1953.
40. 40. INABA K., INABA M., ROMANI N. et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176, 1693.
41. 41. ARTHUR J.F., BUTTERFIELD L.H., ROTH M.D. et al. (1997) A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4, 17.
42. 42. WAN Y., BRAMSON J., CARTER R., GRAHAM F. & GAULDIE J. (1997) Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Human Gene Ther 8, 1355.
43. 43. HANDMAN E. & BURGESS A.W. ( 1979) Stimulation by granulocyte macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J Immunol 122, 1134.
44. 44. KUSHNER B.H. & CHEUNG N.K. (1989) GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73, 1936.
45. 45. CAO X., JU D.W., WANG B.M. et al. (1998) Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Gene Ther 5, 1131.
46. 46. ARCA M.J., KRAUSS J.C., STROME S.E., CAMERON M.J. & CHANG A.F. (1996) Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16 BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 42, 237.
47. 47. ARMSTRONG C.A., BOTELLA R., GALLOWAY T.H. et al. (1996) Antitumor effects of granulocyte macrophage colony-stimulating factor production by melanoma cells. Cancer Res 56, 2191.
48. 48. SCHMIDT W., SCHWEIGHOFFER T., HERBST E. et al. (1995) Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 92, 4711.
49. 49. ROMANI N., GRUNER S., BRANG D. et al. (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180, 83.
50. 50. SZABOLCS P., MOORE M.A. & JOUNG J.W. (1995) Expansion of immunostimulatory dendritic cells among the mycloid progency of human CD34+ bone marrow precusors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol 154, 5851.